Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Dec;10(12):4328-4335.
doi: 10.21037/tlcr-21-830.

Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint

Claire M Faltermeier  1 , Jay M Lee  1
Affiliations
Editorial

Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint

Claire M Faltermeier et al. Transl Lung Cancer Res. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tlcr-21-830). JML reports grants and consulting fees from Astrazeneca, Bristol Myers Squibb, Genentech, Novartis; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astrazeneca, Genentech, Novartis; support from Astrazeneca, Genentech; Participation on a Data Safety Monitoring Board or Advisory Board from UCLA; stock from Moderna. CMF has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Important surgical and clinical endpoints in neoadjuvant trials*. *, adapted from Leeet al. (2). TRAE, treatment related adverse events; OR, operating room; EBL, estimated blood loss; R0, complete resection; ARDS, acute respiratory distress syndrome.
See this image and copyright information in PMC

Comment on

  • Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer.
    Qiu B, Cai K, Chen C, Chen J, Chen KN, Chen QX, Cheng C, Dai TY, Fan J, Fan Z, Hu J, Hu WD, Huang YC, Jiang GN, Jiang J, Jiang T, Jiao WJ, Li HC, Li Q, Liao YD, Liu HX, Liu JF, Liu L, Liu Y, Long H, Luo QQ, Ma HT, Mao NQ, Pan XJ, Tan F, Tan LJ, Tian H, Wang D, Wang WX, Wei L, Wu N, Wu QC, Xiang J, Xu SD, Yang L, Zhang H, Zhang L, Zhang P, Zhang Y, Zhang Z, Zhu K, Zhu Y, Um SW, Oh IJ, Tomita Y, Watanabe S, Nakada T, Seki N, Hida T, Sasada S, Uchino J, Sugimura H, Dermime S, Cappuzzo F, Rizzo S, Cho WC, Crucitti P, Longo F, Lee KY, De Ruysscher D, Vanneste BGL, Furqan M, Sieren JC, Yendamuri S, Merrell KW, Molina JR, Metro G, Califano R, Bongiolatti S, Provencio M, Hofman P, Gao S, He J. Qiu B, et al. Transl Lung Cancer Res. 2021 Sep;10(9):3713-3736. doi: 10.21037/tlcr-21-634. Transl Lung Cancer Res. 2021. PMID: 34733623 Free PMC article. Review. No abstract available.

References

    1. Lee JM, Tsuboi M, Brunelli A. Surgical perspective on neoadjuvant immunotherapy in non-small cell lung cancer. Ann Thorac Surg 2021. [Epub ahead of print].doi: . 10.1016/j.athoracsur.2021.06.069 - DOI - PubMed
    1. Lee JM, Kim AW, Marjanski T, et al. Important surgical and clinical end points in neoadjuvant immunotherapy trials in resectable NSCLC. JTO Clin Res Rep 2021;2:100221. 10.1016/j.jtocrr.2021.100221 - DOI - PMC - PubMed
    1. Lee J, Chaft J, Nicholas A, et al. PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: LCMC3 Trial Primary Analysis. J Thorac Oncol 2021;16:S59-61. 10.1016/j.jtho.2021.01.320 - DOI
    1. Forde PM, Spicer J, Lu S, et al. Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. Cancer Research 2021;81:CT003.
    1. Spicer J, Wang C, Tanaka F, et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). J Thorac Oncol 2021;39:8503.